Abstract:Abstract Genetic variation of alpha-1 antitrypsin (AAT) is responsible for alpha-1-antitrypsin deficiency (AATD) leading to gain-of-toxic aggregation in the liver and loss-of-function on n eutrophil e lastase (NE) inhibitory activity in the lung contributing to c hronic o bstructive p ulmonary d isease (COPD) during aging. To probe the molecular basis for how biology designs the protein fold to achieve balance between sequence, function and structure contributing to AATD in the population, we measured the intracellular monomer and polymer, secreted monomer and polymer and NE inhibitory activity of 75 alpha-1-antitrypsin (AAT) variants. To address the complex folding dynamics affecting the form and function of the protein fold that is differentially impacted by variants in the population, we applied a G aussian p rocess r egression (GPR) based machine learning approach termed v ariation s patial p rofiling (VSP). By using a sparse collection of extant variants to link genotype to phenotype, VSP maps s patial c o v ariance (SCV) relationships that quantitate the functional value of every residue in the wild-type (WT) AAT sequence with defined uncertainty in the context of its protein fold design. The SCV-based uncertainty allows us to pinpoint critical short- and long-range residue interactions involving 3 regions-the N-terminal (N1), middle (M2) and carboxyl-terminal (C3) of AAT polypeptide sequence that differentially contribute to the balance between function and misfolding of AAT, thus providing an unanticipated platform for precision therapeutic development for liver and lung disease. By understanding mechanistically the complex fold design of the metastable WT AAT fold, we posit that GPR-based SCV provides a foundation for understanding the evolutionary design of the fold from the ensemble of structures found in the population driving biology for precision management of AATD in the individual.

Oxidation‐resistant and Thermostable Forms of Alpha‐1 Antitrypsin from Escherichia Coli Inclusion Bodies

Site‐Specific Conjugation of a Selenopolypeptide to Alpha‐1‐antitrypsin Enhances Oxidation Resistance and Pharmacological Properties

Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History

Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice

Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency

Research progress ofα1-antitrypsin deficiency of mutant Z

Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations

Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency

Editing Approaches to Treat Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin in autoimmune diseases: Roles and therapeutic prospects

Alpha1 Antitrypsin and Its Clinic Application

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency

The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease

Profiling Genetic Diversity Reveals the Molecular Basis for Balancing Function with Misfolding in Alpha-1 Antitrypsin

Small airways disease in patients with alpha-1 antitrypsin deficiency

Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry

Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease

Alpha-1 Antitrypsin Induces Epithelial-to-Mesenchymal Transition, Endothelial-to-Mesenchymal Transition, and Drug Resistance in Lung Cancer Cells.

Molecular Mechanism of Z Α1-Antitrypsin Deficiency

Capturing the conversion of the pathogenic alpha-1-antitrypsin fold by ATF6 enhanced proteostasis